A third member of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee resigned in protest over the regulatory agency’s approval of Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease.
Two members of a panel of outside advisors to the U.S. Food and Drug Administration resigned in protest at the regulatory agency’s decision to approve Biogen Inc.’s Aduhelm for the treatment of Alzheimer’s disease despite the committee’s recommendation against doing so.
Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.
Illinois-based Abbott is suing their former VP Jerome Clavel over allegations of trade secret theft with intent to share with his new employer, rival diagnostics company Bio-Rad.
After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role as chief executive officer of Paris-based Ipsen, effective July 1.
Cambridge, Massachusetts-based Unum Therapeutics announced a restructuring in order to shift assets toward the company’s preclinical program, BOXR1030, for solid tumors.
Dynavax CEO Eddie Gray will step down from his role on Aug. 1, 2019, as the Bay Area company undergoes restructuring to move away from immuno-oncology and prioritize the vaccine business.
GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz after being named the new chief executive officer of the Novartis subsidiary.
One is going, one is staying – and getting a promotion.
Novartis’ generics chief stepped down after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.